View in EDS

Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

Saved in:
Bibliographic Details
Title: Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
Authors: Bhatt DL; Mount Sinai Heart, Icahn School of Medicine, Mount Sinai Health System, New York City, NY, USA. dlbhattmd@post.harvard.edu., Bays HE; Louisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, Louisville, KY, USA., Miller M; Corporal Michael J. Crescenz VA Medical Center and Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Cain JE 3rd; Family Medicine Clinic Science, Lampasas, TX, USA., Wasilewska K; ZDROWIE Osteo-Medic, Bialystok, Poland., Andrawis NS; Manassas Clinical Research Center, Manassas, VA, USA., Parli T; 89bio Inc., San Francisco, CA, USA., Feng S; 89bio Inc., San Francisco, CA, USA., Sterling L; 89bio Inc., San Francisco, CA, USA., Tseng L; 89bio Inc., San Francisco, CA, USA., Hartsfield CL; 89bio Inc., San Francisco, CA, USA., Agollah GD; 89bio Inc., San Francisco, CA, USA., Mansbach H; 89bio Inc., San Francisco, CA, USA., Kastelein JJP; Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
Corporate Authors: ENTRIGUE Principal Investigators
Source: Nature medicine [Nat Med] 2024 Jun; Vol. 30 (6), pp. 1788-1789.
Publication Type: Published Erratum
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE; PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38438737
AccessLevel: 2
PubTypeId: unknown
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Bhatt+DL%22">Bhatt DL</searchLink>; Mount Sinai Heart, Icahn School of Medicine, Mount Sinai Health System, New York City, NY, USA. dlbhattmd@post.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Bays+HE%22">Bays HE</searchLink>; Louisville Metabolic and Atherosclerosis Research Center, University of Louisville School of Medicine, Louisville, KY, USA.<br /><searchLink fieldCode="AU" term="%22Miller+M%22">Miller M</searchLink>; Corporal Michael J. Crescenz VA Medical Center and Hospital of the University of Pennsylvania, Philadelphia, PA, USA.<br /><searchLink fieldCode="AU" term="%22Cain+JE+3rd%22">Cain JE 3rd</searchLink>; Family Medicine Clinic Science, Lampasas, TX, USA.<br /><searchLink fieldCode="AU" term="%22Wasilewska+K%22">Wasilewska K</searchLink>; ZDROWIE Osteo-Medic, Bialystok, Poland.<br /><searchLink fieldCode="AU" term="%22Andrawis+NS%22">Andrawis NS</searchLink>; Manassas Clinical Research Center, Manassas, VA, USA.<br /><searchLink fieldCode="AU" term="%22Parli+T%22">Parli T</searchLink>; 89bio Inc., San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Feng+S%22">Feng S</searchLink>; 89bio Inc., San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Sterling+L%22">Sterling L</searchLink>; 89bio Inc., San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Tseng+L%22">Tseng L</searchLink>; 89bio Inc., San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Hartsfield+CL%22">Hartsfield CL</searchLink>; 89bio Inc., San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Agollah+GD%22">Agollah GD</searchLink>; 89bio Inc., San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Mansbach+H%22">Mansbach H</searchLink>; 89bio Inc., San Francisco, CA, USA.<br /><searchLink fieldCode="AU" term="%22Kastelein+JJP%22">Kastelein JJP</searchLink>; Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22ENTRIGUE+Principal+Investigators%22">ENTRIGUE Principal Investigators</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502015%22">Nature medicine</searchLink> [Nat Med] 2024 Jun; Vol. 30 (6), pp. 1788-1789.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Published Erratum
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Publishing+Company%22">Nature Publishing Company </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502015 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1546-170X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210788956%22">10788956 </searchLink><i>NLM ISO Abbreviation: </i>Nat Med <i>Subsets: </i>MEDLINE; PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38438737
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41591-024-02890-2
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1788
    Titles:
      – TitleFull: Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bhatt DL
      – PersonEntity:
          Name:
            NameFull: Bays HE
      – PersonEntity:
          Name:
            NameFull: Miller M
      – PersonEntity:
          Name:
            NameFull: Cain JE 3rd
      – PersonEntity:
          Name:
            NameFull: Wasilewska K
      – PersonEntity:
          Name:
            NameFull: Andrawis NS
      – PersonEntity:
          Name:
            NameFull: Parli T
      – PersonEntity:
          Name:
            NameFull: Feng S
      – PersonEntity:
          Name:
            NameFull: Sterling L
      – PersonEntity:
          Name:
            NameFull: Tseng L
      – PersonEntity:
          Name:
            NameFull: Hartsfield CL
      – PersonEntity:
          Name:
            NameFull: Agollah GD
      – PersonEntity:
          Name:
            NameFull: Mansbach H
      – PersonEntity:
          Name:
            NameFull: Kastelein JJP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2024 Jun
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1546-170X
          Numbering:
            – Type: volume
              Value: 30
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Nature medicine
              Type: main
ResultId 1